| | A Field Guide to Cancer Progression
Tag along with the Whitehead Institute’s “Cells Over Time” series to explore key moments of cancer progression. First stop: Jaenisch Lab, where chimeras shed new light on the cellular origins of neuroblastoma. In collaboration with the Spranger Lab, the researchers investigate how newly formed cancer cells “trick” immune cells into not destroying them. Spranger Lab technologies are also being used in the Weinberg Lab to understand the changes that occur when breast cancer cells become metastatic and acclimate to far-flung homes. Of course, this whirlwind tour would not be complete without a visit to the Weissman Lab where researchers have adapted a lung cancer model developed by the Jacks Lab to analyze gene expression as tumors evolve. Together, these intrepid explorers are charting a way forward in cancer biology. |
|
Scientific Modeling
Paula Hammond guest edits C&EN’s 2021 Trailblazers issue, highlighting the achievements of Black chemists and engineers in their own voices. Amid the reflections on past and present research, accomplishment and inclusion, career origins and evolutions, don’t miss Hammond’s own profile, tracing her path from young nerd to nanomaterials pioneer. |
|
|
Next Stop KRAS
The FDA approved biotech startup Elicio will begin clinical testing of their “hitchhiking” therapeutic vaccine candidate designed to target mutated KRAS cancers using the Irvine Lab's signature lymph node targeting technology. The trial will enroll patients with mKRAS+ pancreatic ductal adenocarcinoma and other solid tumors. |
|
|
Behind the Vaccines
Beneath every great biotech innovation lies many years of research. KI members Phil Sharp and Robert Langer reflect on the early days of RNA discovery and innovation in a Tech Review feature by MIT President Rafael Reif, profiling the Institute’s contributions to Moderna’s “overnight” success developing an mRNA vaccine for COVID-19. Both Sharp’s work on mRNAs and Langer’s on lipid nanoparticles began in the 1970’s. Similarly, both play an increasingly important role in human health, advancing new tools to fight COVID, cancer and other diseases. |
|
|
The Companies They Keep
The Future Founders Initiative is off and running, making important strides to increase the number of woman-founded companies in biotech. Led by KI members Sangeeta Bhatia and Harvey Lodish, the initiative builds on Bhatia's recent work with Susan Hockfield and Nancy Hopkins around gender disparities in entrepreneurship, focusing on networking and community building. |
|
|
Progress Against Prostate Cancer Proceeds
Positive data continue to emerge from Phase II clinical trials in advanced prostate cancer of a synergistic drug combination identified by the Yaffe Lab. Fine-tuning the dosing schedule more than doubled the percentage of patients whose cancer stabilized or responded positively to treatment. Ongoing biomarker research in the Yaffe Lab has revealed genetic mutations that may help clinicians predict treatment response to the combination and support efficient design of future trials. This trial and related research have been funded in part by the Bridge Project and the MIT Center for Precision Cancer Medicine. |
|
|
Inside an Immune Response
Working with collaborators to collect longitudinal samples during clinical trials of a new treatment technique for brain hemorrhage, the Love and Shalek Labs have published a new study in Science Immunology illuminating immune activity in acute injury. The team’s data show an evolution of macrophages, a type of immune cell, from a pro-inflammatory to anti-inflammatory state. The researchers also saw metabolic shifts, and found glycolytic metabolism—normally seen in cancer cells—in the macrophages was associated with better patient outcomes. These types of transitions in macrophage inflammation and metabolism are also known to be important in cancer, for which these findings provide additional insights and reference points. |
|
|
New Immunotherapy Target in Glioblastoma
A new paper in Cell from a Bridge Project team working on brain cancer sheds light on how gene expression in T cells affects response to immunotherapy in tumors called gliomas. Single-cell RNA sequencing approaches developed in the Regev Lab highlighted the role of KLRB1. Silencing this gene in cell and animal models enhanced T cell killing of glioma cells, suggesting its utility as an immunotherapy target. |
|
|
Tying Up Loose Ends in RNA Therapeutics
Orna, co-founded by KI member Daniel Anderson and based on strategies developed in his lab offers an alternative to current RNA-based therapies. By connecting the loose ends of linear messenger RNA molecules, Orna’s circularized “oRNAs” could improve stability of mRNA therapies, leading to more efficient delivery of drugs into cells and increased expression of disease-fighting proteins. The company will develop and test their approach in the area of cancer immunotherapy. |
|
|
|
| | | | |
|
